Overview
Title
To amend the Public Health Service Act to authorize and support the creation and dissemination of cardiomyopathy education, awareness, and risk assessment materials and resources to identify more at-risk families, to authorize research and surveillance activities relating to cardiomyopathy, and for other purposes.
ELI5 AI
This bill wants to teach people more about a heart problem called cardiomyopathy by sharing information with schools and doctors and also wants to help scientists study this condition to find ways to help people with it.
Summary AI
H.R. 6829, known as the "Cardiomyopathy Health Education, Awareness, Research, and Training in the Schools Act of 2023" or the "HEARTS Act of 2023," aims to promote awareness and understanding of cardiomyopathy. It directs the development and distribution of education materials to schools and health professionals to raise awareness and provide training on handling cardiac emergencies, such as placing and using defibrillators in educational settings. The bill also supports research by the CDC and NIH to study the prevalence, impact, and treatment of cardiomyopathy, with an emphasis on both pediatric and adult populations. Additionally, it authorizes funding for these initiatives and sets timelines for developing resources and reporting findings.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The proposed legislation, titled the Cardiomyopathy Health Education, Awareness, Research, and Training in the Schools Act of 2023, or HEARTS Act of 2023, seeks to amend the Public Health Service Act. The bill focuses on increasing education and awareness of cardiomyopathy, a heart disease affecting the heart muscle, among school administrators, educators, and families. It mandates the development and dissemination of educational materials and guidelines, as well as the placement of automated external defibrillators in schools. Additionally, the bill authorizes research and surveillance activities conducted by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) to better understand the disease's prevalence, causes, and impacts.
Summary of Significant Issues
Several issues arise from the bill's current draft. Notably, the bill authorizes $5 million annually from 2025 to 2028 for education and research purposes without detailing specific allocation plans or expected outcomes. This lack of budgetary precision poses a risk of inefficiencies or wasteful spending. The timeline for the development and dissemination of educational materials and the final reporting on research is also seen as potentially too extensive, delaying impactful measures.
Additionally, the bill makes multiple mentions of important terms, such as "risk assessment" and "cardiac emergency response plan," which are left without clear definitions or guidelines, leading to the risk of misinterpretation. Furthermore, the selection process for external stakeholders and the nature of their involvement remain vague, potentially leaving room for favoritism or exclusion. Lastly, privacy considerations are mentioned, but the specifics regarding data handling are not elaborated on, which might not sufficiently address related concerns.
Potential Impact on the Public
The bill's impact on the public could be significant, particularly in how it seeks to improve the awareness and preparedness of schools in dealing with cardiomyopathy. By mandating educational materials and resources, the legislation aims to reduce the risks associated with this heart condition through increased knowledge and better emergency response in schools. This could potentially save lives by enabling quicker responses to cardiac emergencies.
However, the broad language and lack of specificity regarding budget allocation and stakeholder involvement could lead to inefficiencies, ultimately affecting the effectiveness and reach of the proposed measures. Additionally, the extended timelines might delay the implementation of critical educational and research initiatives, somewhat mitigating their overall positive impact on public health.
Potential Impact on Specific Stakeholders
For school administrators, educators, and healthcare professionals, this bill offers a framework to enhance their ability to respond to cardiomyopathy-related incidents. By equipping them with training and resources, they stand to significantly benefit from the legislation. Parents and families may also feel more secure knowing that educational institutions are better prepared to handle such medical emergencies.
Healthcare professionals involved in the development and dissemination of resources may face challenges due to the lack of defined processes and criteria for their participation. Additionally, without clearly set benchmarks for success, institutions responsible for implementing the bill's provisions might struggle with accountability, affecting both their operations and public trust.
In summary, while the HEARTS Act of 2023 proposes well-intentioned measures that could positively impact public health by enhancing awareness and preparedness for cardiomyopathy, the bill would benefit from greater specificity and clarity to ensure efficient and equitable implementation.
Financial Assessment
The bill H.R. 6829, titled the "Cardiomyopathy Health Education, Awareness, Research, and Training in the Schools Act of 2023," allocates financial resources aimed at enhancing education and research related to cardiomyopathy. Below is an analysis of how these financial allocations are structured and their potential implications.
Financial Allocations Summary
The bill authorizes $5,000,000 annually from fiscal years 2025 to 2028 for developing and disseminating educational materials and resources, as well as for conducting research and surveillance on cardiomyopathy. These funds are specifically earmarked for sections detailing the development of educational resources and research activities under the CDC and NIH.
Issues Related to Financial Allocations
Lack of Detailed Budgetary Planning: The appropriation of $5,000,000 per year does not outline specific allocations within the budget for various activities such as education material development, dissemination, and specific research initiatives. This broad allocation could result in potential inefficiencies or wasteful spending if not properly monitored and reported.
Extended Timelines and Financial Implications: The timelines set for the dissemination of educational materials (30 months after enactment) and the final report on research (due January 1, 2029) might delay impactful use of funds. Long lead times can incur additional administrative and operational costs, affecting the funds' efficiency and impact.
Unspecified Budget for Surveillance Activities: Section 3 mentions research and surveillance activities without specific financial allocations for these tasks, leading to uncertainty about whether adequate resources are dedicated to these critical components of the bill. This lack of financial clarity could hinder effective implementation of research goals.
Evaluation of Stakeholder Input Process: The lack of clarity on how external stakeholders will be selected and how their input will affect financial decisions can lead to uneven influence over how funds are distributed or prioritized. Ensuring transparency in this process is crucial for the equitable and effective use of the authorized budget.
Broadly Defined Research Directive: In Section 404F, the call to expand, intensify, and coordinate research lacks precise guidelines, which might lead to an unfocused allocation of resources. This broad approach necessitates stringent oversight to ensure that finances are directed towards the most impactful and scientifically robust research projects.
By effectively addressing these financial-related issues, the bill can maximize its allocated resources, ensuring that funds drive significant advancements in cardiomyopathy education, awareness, and research. Clearer guidelines and accountability measures for financial allocations are essential to the successful implementation and achievement of the bill’s goals.
Issues
The bill lacks detailed budgetary planning, as Section 2 and Section 399V-9 authorize $5,000,000 per year for education and research activities without specifying how these funds will be specifically allocated. This could lead to potential inefficiencies or wasteful spending.
The timelines for the dissemination of educational materials and resources in Section 2 and for the final report on cardiomyopathy research in Section 399V-9 are extensive, potentially delaying crucial actions and information dissemination crucial for public health and safety.
There is an absence of explicit definitions or guidelines for key terms like 'risk assessment' and 'cardiac emergency response plan' in Section 399V-8, which might lead to misinterpretations or inconsistent implementations.
Section 3 lacks specificity regarding budget or funding allocations necessary to carry out research and surveillance activities, leading to uncertainty about the availability of resources needed for these initiatives.
The roles and the selection process for external stakeholders involved in Section 3 are unclear, which could lead to favoritism or the exclusion of potentially valuable contributors.
In Section 404F, the directive to expand, intensify, and coordinate research on cardiomyopathy is broadly defined, which could lead to funding being directed without clear guidelines, accountability, or objectives.
Privacy protections in the public dissemination of research reports in Section 399V-9 seem only to comply with existing laws, which may not sufficiently address stakeholders’ concerns about data handling specifics, potentially leading to ethical issues.
The plan to make reports publicly available includes undefined terms, such as what 'make publicly available' entails in Section 399V-9, which could result in accessibility issues for the intended audience.
The use of technical medical terminology without lay explanations in Sections 3 and 404F could make the text difficult for non-experts to understand, potentially limiting the bill's accessibility and utility for the general public.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the bill states that it can be officially called the “Cardiomyopathy Health Education, Awareness, Research, and Training in the Schools Act of 2023” or simply the “HEARTS Act of 2023”.
2. Materials and resources to increase education and awareness of cardiomyopathy among school administrators, educators, and families Read Opens in new tab
Summary AI
The section proposes the development and dissemination of public education materials to increase awareness of cardiomyopathy among school-related individuals within 18 months of the act's passage. It outlines plans for distributing this information through State educational agencies, health departments, and online resources, and allocates $5 million annually from 2025 to 2028 for these efforts.
Money References
- “(d) Authorization of appropriations.—For carrying out this section and section 399V–9, there is authorized to be appropriated $5,000,000 for each of fiscal years 2025 through 2028.”.
399V–8. Materials and resources to increase education and awareness of cardiomyopathy among school administrators, educators, and families Read Opens in new tab
Summary AI
The bill mandates the development and distribution of educational materials about cardiomyopathy to schools and health professionals, including guidelines for emergency response and defibrillator use, to raise awareness and improve response to cardiac emergencies in educational settings. Additionally, it allocates a budget of $5 million annually from 2025 to 2028 for this purpose.
Money References
- (d) Authorization of appropriations.—For carrying out this section and section 399V–9, there is authorized to be appropriated $5,000,000 for each of fiscal years 2025 through 2028. ---
3. Research and surveillance activities relating to cardiomyopathy Read Opens in new tab
Summary AI
The law tasks the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) with conducting research and surveillance on cardiomyopathy, a heart disease affecting the heart muscle. The CDC must report findings on the disease's prevalence and healthcare impacts, while the NIH is encouraged to delve into its causes and outcomes.
399V–9. Research and surveillance activities relating to cardiomyopathy Read Opens in new tab
Summary AI
The section outlines that the Centers for Disease Control and Prevention (CDC) will provide reports and develop risk assessments to better understand and manage cardiomyopathy, a heart muscle disease. The reports, due initially in 2024 and finally in 2029, will cover the prevalence, healthcare costs, and hospital visits for individuals with cardiomyopathy, while the risk assessments will include information for individuals at risk and guidelines for screenings, with input from various stakeholders.
404F. Cardiomyopathy research Read Opens in new tab
Summary AI
The section outlines that the Director of the National Institutes of Health (NIH) can enhance and coordinate research efforts related to cardiomyopathy, a heart disease affecting the heart muscle, focusing on causes, long-term effects, and treatment effectiveness. It defines cardiomyopathy as a condition with symptoms ranging from none to severe heart issues and recognizes several types, including dilated and hypertrophic cardiomyopathy.